ORYZON Raises €12 Million and Signs a Financing Agreement with COFIDES to Strengthen its Balance Sheet and Accelerate its Clinical Programs
MADRID and CAMBRIDGE, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced the successful completion of a €12 million gross capital increase through the issuance of 4,444,445 new ordinary shares, at a subscription price of €2.70 per share. This pricing represents a 14.15% discount to the five-day volume-weighted average price (VWAP), which was €3.1449, and a
MADRID and CAMBRIDGE, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced the successful completion of a €12 million gross capital increase through the issuance of 4,444,445 new ordinary shares, at a subscription price of €2.70 per share. This pricing represents a 14.15% discount to the five-day volume-weighted average price (VWAP), which was €3.1449, and a 12.68% discount to the June 30 closing price of €3.092 per share. The offering was structured as a capital increase without the issuance of warrants. Singular Bank acted as placement agent in Spain, and All-Invest acted as placement agent in the EU and the UK. Banco Sabadell, S.A. acted as Agent Bank and Technical Pre-Financing Entity for the capital increase, while Gómez-Acebo & Pombo Abogados, S.L.P. acted as legal counsel to the Company.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.